MDB Capital acted as the underwriter of the public offering, and Cambria Capital LLC and Paulson Investment Company LLC participated as selected dealers. Golenbock Eiseman Assor Bell & Peskoe LLP ...

Vivos’ cost-cutting initiatives also led to a $1 million or 27% year-over-year reduction in operating loss, versus the third quarter of 2023. For the nine months ended September 30, 2024 operating ...

Cash and Cash Equivalents: As of September 30, 2024, Senti Bio held cash and cash equivalents of $10.5 million. Subsequent to quarter-end, the Company received $2.5 million, the second tranche of an ...

Third Quarter 2024 Financial Results Collaboration revenue increased by $1.2 million to $3.3 million for the three months ended September 30, 2024, from $2.1 million for the three months ended ...

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today reported financial results for the quarter ended ...

Long-term Efficacy Results of Diazoxide Choline Extended-Release (DCCR) Tablets in Participants with Prader-Willi Syndrome from the Completed C601 (DESTINY PWS) and C602 Open Label Extension (OLE) ...

Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025 Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive ...

If you are interested in requesting a one-on-one meeting at the conference, please contact your Piper Sandler representative. About Beyond Air®, Inc. Beyond Air is a commercial stage medical device ...

An oral presentation at the Michael J. Fox Foundation’s 16 th Annual Parkinson’s Disease Therapeutics Conference in October 2024 in New York, NY. A virtual webinar hosted by Gain Therapeutics in ...

Third Quarter 2024 Financial Results Total revenue for the third quarter of 2024 was $2.0 million, an increase of 34% compared to the prior year period. Sepsis test revenue grew 34% compared to the ...

In October 2024, following suspension of the current SPR720 development plans, Spero underwent a restructuring and reduction in force of approximately 39%, which extended the Company’s cash runway ...

Revenue: Revenue was $4.7 million for the three months ended September 30, 2024, compared to $6.9 million for the same period in 2023. The decrease was primarily due to lower partnering revenues as a ...